News
FEATURED STORIES
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked assets, as well as AI-driven drugmakers.
Viking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
THE LATEST
Forbion participated in the November 2025 series B round of Gate Bioscience, which earlier this week inked an up to $870 million deal extension with Eli Lilly.
Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.
The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
The person you expect to address the company’s problems should know the challenges your business faces. Not having that context will limit what they can accomplish.
With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-telangiectasia, according to Jefferies.
Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche’s Polivy.
While AI is taking off in biopharma for administrative tasks and drug discovery efforts, more than 90% of drugmakers have yet to commit to scaling AI use in regulated biopharma manufacturing, according to CRB’s new Horizons: Life Sciences report.
40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-front and up to $1.225 billion in total consideration.